Health Care as a Human Right? Why Not?

multiracial hands embraced

SPONSORED CONTENT

Let’s get this right out on the table: At Avita, we believe health care is a human right.

Polarizing politics aside, as an advanced, civilized society, we have an ethical obligation to care for the medical needs of every U.S. citizen compassionately and equitably, regardless of their race, gender, sexual identity, or ability to pay. It’s a principle our covered entity partners fight for daily, not to mention a pivotal reason behind the creation of the 340B program: Together, we must use every resource at our disposal to serve the underserved—forming a “safety-net” that catches patients who might otherwise fall through the cracks—and empower them to unlock the full potential of health.

But the truth is that alleviating the nation’s massive health equity crisis will take both introspection and innovative thinking from every single player in the industry, including 340B service providers, covered entities, drug manufacturers…the list goes on and on. Earlier

Read More »

340B Hospitals Use Biosimilars Less Than Others, PhRMA-Commissioned Study Finds

graphic image of biosimilar pills depicted equal on a scale
340B hospitals use biosimilar drugs less than other hospitals, a PhRMA-funded study found.

340B hospitals use biosimilar drugs less than other hospitals, which may expose patients to higher out-of-pocket costs, a drug industry funded study concludes.

Pharmaceutical Research and Manufacturers of America released the study last week. Healthcare consulting firm Milliman did the research for

Read More »

340B Prime Vendor Sued for Allegedly Not Negotiating Sub-Ceiling Pricing on HIV/AIDS Drugs

Screenshot of complaint AHF v. Apexus
AIDS Healthcare Foundation says in a lawsuit that Apexus, the 340B prime vendor, fails and refuses to negotiate sub-ceiling 340B discounts on HIV/AIDS medicines.

AIDS Healthcare Foundation sued Apexus, the federally contracted 340B prime vendor, on Friday for allegedly failing and refusing to negotiate sub-ceiling 340B discounts on HIV/AIDS prescription drugs pursuant to its agreement with the government.

An Apexus spokesperson yesterday said it

Read More »

Arkansas Health System Asks State to Enforce its 340B Contract Pharmacy Law Against Novo Nordisk

Arkansas Insurance Department office sign
An Arkansas health system has asked state insurance officials to enforce the state's 340B contract pharmacy anti-discrimination law against Novo Nordisk.

An Arkansas health system is urging state officials to enforce the state’s novel 340B contract pharmacy anti-discrimination law against drug maker Novo Nordisk to end the company’s restrictions on 340B-priced drugs dispensed at multiple contract pharmacies. The lawsuit marks the

Read More »

Important Operational Insights for Covered Entities Choosing to Access 340B ESP

SPONSORED CONTENT

Alas, after much deliberation, your covered entity has decided to submit data to 340B ESP. As you embark on this journey, you may be asking yourself: Now what?!?  

As someone who has operated a large 340B program at a DSH hospital and now has the privilege to consult many covered entities as they tackle 340B challenges, I know that making a decision and then operationalizing that decision can be quite the task! Many of our covered entity clients have decided to start submitting claims data to 340B ESP. While assisting our clients in navigating these uncharted waters, The Alinea Group has developed insights we want to share with the covered entity community. 

Initial Upload

The first step in getting access to 340B pricing is to upload an initial set of claims. This can be a difficult task, as many Third-Party Administrators (TPAs) have blocked these claims from qualifying as 340B claims once pricing for these

Read More »

CMS Defends Delayed Fix for Illegal Medicare Drug Payment Cuts for 340B Hospitals

pill bottle and Medicare health insurance card
CMS defends its decision to wait until next year to decide how to remedy illegal past cuts in 340B hospitals Part B drug reimbursement.

Federal health officials last week defended their plan to wait until next year to say how they will reimburse 340B hospitals for illegal Medicare Part B drug payment cuts in place for the past five years after hospital groups told

Read More »

HRSA Sanctions Manufacturer for Not Issuing Refund for 340B Overcharges

KVK Tech office building
HRSA has ordered Pennsylvania-based generic drug manufacturer KVK Tech to repay 340B covered entities for program violations found during an audit.

The U.S. Health Resources and Services Administration has ordered Pennsylvania-based generic drug manufacturer KVK Tech to repay 340B covered entities for program violations found during an audit.

HRSA posted its audit findings Nov. 15. “KVK-Tech failed to refund covered entities for

Read More »

White House Gives HRSA Green Light to Publish Proposed New 340B Dispute Resolution Regulations

Screenshot of reginfo.gov 340B program ADR record
The White House yesterday authorized HRSA to publish a proposed rule to replace the 340B administrative dispute resolution final rule HRSA promulgated in late December 2020.

The White House yesterday unexpectedly gave the U.S. Health Resources and Services Administration permission to publish a proposed replacement for HRSA’s December 2020 340B administrative dispute resolution final rule.

The Office of Management and Budget announced on its website Nov.

Read More »

A Closer Look at Tuesday’s Arguments in Federal Appeals Court Over the Legality of the 340B Contract Pharmacy Program

Third Circuit Court building entrance
Today 340B Report takes a closer look at Tuesday's oral arguments in federal circuit court in Philadelphia in three 340B contract pharmacy lawsuits.

On Tuesday we reported about oral arguments before a federal appeals court in Philadelphia in AstraZeneca, Novo Nordisk, and Sanofi’s lawsuits challenging federal agency findings that the companies’ conditions on 340B covered entities’ use of contract pharmacies violate the 340B statute.

Read More »

Optimize Specialty Pharmacy Outcomes at ASHP Midyear in Las Vegas

SPONSORED CONTENT

Gain insights from Omnicell Specialty Pharmacy Services thought leaders and Bausch Health during an informative panel-style discussion to deliver proven best practices for optimizing specialty pharmacy to enhance patient outcomes.

This session will take place December 6 from 11:30 AM – 12:30 PM at the ASHP Midyear.

Attendees will learn how to:

  • Navigate the complexities of getting specialty medications to patients in a timely manner
  • Establish strong relationships with pharmaceutical manufacturers that improve access to Limited Distribution Drugs (LDDs) to better serve patient needs
  • Best manage payer interactions to expedite specialty medication prior authorizations and approvals
  • Optimize patient outcomes through improved medication adherence in specialty programs, reducing hospital readmissions

Don’t miss this must-attend Promotional Theater session titled Advancing Adherence and Clinical Outcomes in Specialty Pharmacy.


Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report